New chemo combo aims to shrink aggressive breast cancer before surgery

NCT ID NCT01525966

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial is testing whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The goal is to see if this approach increases the rate of complete remission (no cancer left at surgery) from the historical 20% to 38%. About 67 participants will receive the drugs intravenously before their surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
carboplatin and nab-paclitaxel (chemotherapy drugs)
What this could lead to
If this works, it could show that this chemotherapy combination before surgery helps more patients achieve complete remission, potentially reducing the need for extensive surgery.
What could go wrong
This is a phase II trial with only 67 participants, so results may not apply to all patients. Chemotherapy side effects like low blood counts and nerve damage are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESTROGEN RECEPTOR NEGATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

  • City of Hope- South Pasadena Cancer Center

    South Pasadena, California, 91030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.